Recently identified gene mutation increases the risk of developing type 2 diabetes tenfold. It was found in the DNA of the population of Greenland.
 
The study by scientists from Copenhagen gives a new perspective on innate predisposition and the real danger of diabetes.
 
Of course, the presence of the mutation TBC1D4, is not confined only within the largest island on the planet. It has already detected among many Europeans suffering from diabetes.
 
Its "arms" consists in the development of insulin resistance in muscle.
 
The discovery allows for harder prevention of diseases and the development of new techniques for treatment.
 
"We know that each of us has his heredity, which, unfortunately, when diabetes is critical. It is not enough to become diabetics. We do not inherit the disease, and the tendency of its manifestation.
 
Our meeting with a number of external factors such as viruses, chemicals, and other stressful situations may trigger a series of autoimmune processes in our body that damage and destroy cells of the pancreas that produce the hormone insulin, "comment the investigators.
 
They point out that diabetes is not a disease, as it causes many damages to the human body.
 
"We can not change our heredity, but we can change our lifestyle.
 
If you take care of your health in time through healthy eating and daily physical activity we can gain skills for coping with stress alone can reduce the likelihood of falling ill from diabetes, "concluded the report by researchers from Copenhagen.

ADWX-1 is an optimised synthetic analog of the scorpion peptide BmKTx. ADWX-1 is known to block voltage-gated K_v1.3 channel with a high affinity (IC₅₀ = 1.89 pM) and selectivity (340 fold greater affinity than for voltage-dependent ).ADWX-1 inhibits CD4⁺ CCR7^- T-cell proliferation. ADWX-1 is an interesting therapeutic candidate to treat auto-immune disorders such as multiple sclerosis, type-1 diabetes, rheumatoid arthritis and psoriasis. This peptide is a valuable tool for studying the structure-function of K_v1.3 channel and auto-immunity pathways.

Product Specifications

AA sequence: Val-Gly-Ile-Asn-Val-Lys-Cys⁷-Lys-His-Ser-Arg-Gln-Cys¹³-Leu-Lys-Pro-Cys¹⁷-Lys-Asp-Ala-Gly-Met-Arg-Phe-Gly-Lys-Cys²⁷-Thr-Asn-Gly-Lys-Cys³²-His-Cys³⁴-Thr-Pro-Lys-OH
Disulfide bonds between: Cys⁷-Cys²⁷, Cys¹³-Cys³², Cys¹⁷-Cys³⁴
Length (aa): 37
Formula: C₁₆₉H₂₈₁N₅₇O₄₆S₇ 
Molecular Weight: 4071.90 Da 
Purity rate: > 98%
Appearance: White lyophilized solid
Solubility: water and saline buffer
CAS number: not available
Source: Synthetic

Catalog N° 13ADW001

Antidepressant duloxetine effectively treat peripheral neuropathy induced by chemotherapy showed a phase III clinical study published in the Journal of the American Medical Association.

According to Ellen Smith of the University of Michigan in Ann Arbor, after 5 weeks of treatment, patients receiving duloxetine experienced a significant reduction in morbidity compared with placebo.

Peripheral neuropathy occurs in 20-40% of patients treated with neurotoxic chemotherapy. Such fees are (paclitaxel, docetaxel, etc.)., Vinca alkaloids (vincristine, vinblastine) and platinum compounds (cisplatin, oxaliplatin, etc.).. The condition can persist for years after treatment and greatly reduced quality of life.

Previous studies have shown that inhiborite reuptake of serotonin and norepinephrine (class of antidepressants) have the potential to influence the state. Duloxetine also is known to reduce morbidity and diabetic neuropathy.

In order to clarify the properties of duloxetine, the researchers conducted a randomized, double-blind, placebo-controlled study in 220 patients with stage I or greater sensory neuropathy induced by anti-cancer therapy. All participants were over the age of 25 and assessed their painful 10-ball standard scale, three months after the completion of a chemotherapy course. Half the patients received duloxetine and half - placebo, allocation is done randomly. The soreness was re-assessed after the study.

The end result of the study shows that 5-week treatment with duloxetine significantly reduces morbidity in peripheral neuropathy. This, in turn, enhances the quality of life and employability of patients. The benefits of duloxetine seem greatest for people who have completed chemotherapy with platinum compounds.

The most common side effects of duloxetine documented during the study were fatigue, insomnia and nausea.
 
Although good design of the study does not include follow-up of patients for an extended period, so it is impossible to tell how lasting are the effects of duloxetine in this indication.